NCT06960538Completed
Enpowering Progression Risk of Cerebral Amyloid Angiopathy
PRIORITY (Enpowering Progression Risk of Cerebral Amyloid Angiopathy)
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical manifestations. Despite recent advances in diagnosis and understanding, many pathogenic, prognostic, and therapeutic aspects remain unclear. Study Objective: PRIORITY is a prospective observational study aimed at identifying clinical, neuroradiological, and biochemical biomarkers that could improve early diagnosis, risk stratification, and the identification of personalized therapeutic targets for CAA.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 2 Apr 2025
- Start date
- 1 Nov 2021
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- NCT number
- NCT06960538
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 1 Nov 2021 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients who are unable to provide informed consent for the study due to aphasic or cognitive impairment;
Other
- patients who have contraindications to undergoing brain MRI (e.g., pacemaker, incompatible mechanical valves, claustrophobia);
- patients who have contraindications to or refuse to undergo lumbar puncture;
- patients who are pregnant or breastfeeding.
Who the study is looking for
- patients of either sex over 18 years of age;
- patients with possible and probable symptomatic or asymptomatic CAA with or without histological demonstration (modified Boston criteria);
- patients who have had at least one brain MRI.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Istituto Neurologico Carlo Besta Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.